Know Cancer

or
forgot password

Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care


Phase 4
18 Years
65 Years
Not Enrolling
Both
Acute Myeloid Leukemia

Thank you

Trial Information

Prospective Observational Study of Mylotarg (Gemtuzumab Ozogamicin) in Usual Care


Inclusion Criteria:



- Treated by Mylotarg

- Provide ICF

Type of Study:

Observational

Study Design:

Observational Model: Defined Population, Observational Model: Natural History, Time Perspective: Longitudinal, Time Perspective: Prospective

Principal Investigator

Medical Monitor

Investigator Role:

Study Director

Investigator Affiliation:

Wyeth is now a wholly owned subsidiary of Pfizer

Authority:

United States: Institutional Review Board

Study ID:

0903X-100847

NCT ID:

NCT00161668

Start Date:

October 2001

Completion Date:

Related Keywords:

  • Acute Myeloid Leukemia
  • Leukemia
  • Leukemia
  • Leukemia, Myeloid, Acute
  • Leukemia, Myeloid

Name

Location

Hinsdale, Illinois  60521
Bettendorf, Iowa  52722
Phoenix, Arizona  85012
Fountain Valley, California  92708
Miami, Florida  33176
Columbia, Missouri  65203
Albany, New York  12208
Cleveland, Ohio  44195
Philadelphia, Pennsylvania  19104
Nashville, Tennessee  37203-1632
Austin, Texas  78705
Flint, Michigan  48532
Louisville, Kentucky  40207
McLean, Virginia  22101
Hackensack, New Jersey  07601
Albuquerque, New Mexico  87131-5636
Metairie, Louisiana  70006
Denver, Colorado  
Charlotte, North Carolina  
Eugene, Oregon  
Milwaukee, Wisconsin  
Indianapolis, Indiana  
Tulsa, Oklahoma  
Charleston, West Virginia  25304
Bismarck, North Dakota  58501